Background/Objectives: Robot-assisted therapy (RAT) can deliver repetitive, feedback-enriched upper-limb practice after stroke, but evidence comparing RAT with dose-matched conventional occupational therapy (COT) under routine inpatient conditions—and concurrent neurocognitive data—remains limited. We compared motor recovery between an end-effector RAT-based program (30 min RAT plus 30 min COT) and dose-matched COT alone in subacute stroke survivors, with neurocognitive outcomes prespecified as exploratory endpoints. Methods: In this single-center retrospective non-randomized cohort study, adults with first-ever ischemic or hemorrhagic stroke who completed routine baseline and week−4 assessments received 4 weeks of upper-limb rehabilitation: combined RAT plus COT (60 min daily) or COT alone (60 min daily). The primary outcome was the week-4 Fugl–Meyer Assessment–Upper Extremity (FMA-UE) motor score adjusted for baseline. Primary inference used covariate-adjusted linear regression on outcome-specific complete cases, with a prespecified stabilized inverse probability of treatment weighting (IPTW) average treatment effect analysis as the sensitivity test. Secondary and exploratory endpoints were interpreted descriptively; Benjamini–Hochberg false discovery rate (FDR) control and multiple imputation were applied as supportive analyses. Results: The analytic cohort comprised 65 patients (RAT, n = 33; COT alone, n = 32). Both groups improved over 4 weeks, but the RAT group had worse baseline upper-limb motor status. The adjusted between-group difference for the week-4 FMA-UE motor score was non-significant (adjusted mean difference, 4.39; 95% confidence interval (CI), −2.43 to 11.21; p = 0.203), and the stabilized IPTW estimate was concordant (β = 2.17; 95% CI, −3.63 to 7.98; p = 0.464). In unadjusted analyses, the FMA-UE motor gain was larger after RAT than COT alone (14.70 ± 15.53 vs. 7.91 ± 9.42), and only the RAT group exceeded the prespecified 12.4-point clinically important threshold; this signal attenuated after adjustment. No secondary or exploratory endpoint remained significant after FDR control. Multiple imputation for the primary endpoint was concordant with the complete-case result (pooled β = 4.52; 95% CI, −1.91 to 10.94; p = 0.168). Conclusions: End-effector RAT did not demonstrate adjusted superiority over dose-matched COT alone for upper-limb motor recovery. The larger unadjusted FMA-UE gain should be interpreted as a descriptive impairment-level signal rather than as evidence of comparative efficacy. Neurocognitive results were exploratory; the retrospective non-randomized design, baseline imbalance, differential missingness, and unavailable confounder data require cautious interpretation.
Background: Helmet therapy is considered to be a treatment for infants with positional plagiocephaly. Although some studies suggest that anterior fontanelle (AF) size may also affect treatment outcomes, evidence and influence remain unclear. The aim of this study is to assess the impact of anterior fontanelle size on the effectiveness of helmet therapy, with the goal of determining the optimal timing and patient criteria for treatment. Methods: We conducted a retrospective study of 94 infants treated with helmet therapy for positional plagiocephaly at Kwangju Christian Hospital between January 2020 and December 2021. Patients were divided into two age groups (≤6 months and >6 months) and three SAF quartiles (≤25%, 25–75%, ≥75%). Parameters reflecting the degree of cranial asymmetry correction, including cranial vault asymmetry (CVA) and cranial vault asymmetry index (CVAI), were recorded at the start and end of treatment. Results: Infants aged ≤6 months showed significantly greater improvements in cranial vault asymmetry (CVA) and cranial vault asymmetry index (CVAI) compared to older infants (CVA: 4.57 ± 2.30 mm vs. 7.04 ± 3.85 mm, p = 0.003; CVAI: 3.10 ± 1.55% vs. 4.45 ± 2.44%, p = 0.011). When analyzed by anterior fontanelle (AF) size quartiles (≤25%, 25–75%, ≥75%), no significant differences in treatment outcomes were observed at the end of therapy for CVA (p = 0.88) or CVAI (p = 0.91). In infants ≤6 months, SAF quartile analysis also showed no significant differences in CVA (p = 0.97) or CVAI (p = 0.98) improvements. Conclusions: Our findings indicate that anterior fontanelle size is not a predictor of helmet therapy outcomes in positional plagiocephaly. Early initiation of helmet therapy (≤6 months) remains the most critical factor for achieving optimal results.